Xeris Biopharma Holdings, Inc. 4

Chief Legal Officer Beth Hecht sold 16,666 shares of Xeris Biopharma Holdings, Inc. common stock at about $8.03 per share under a Rule 10b5-1 plan.

On July 1, 2026, Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., sold 16,666 shares of the company’s common stock at a weighted average price of approximately $8.03 per share, for total proceeds of about $133,850, under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. Following this sale, she reported direct ownership of 1,161,128 shares of common stock, which includes 1,288 shares acquired a day earlier on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan. Using the reported transaction price as a proxy for the current market price, her post-transaction holdings are valued at roughly $9.33 million.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

sec

Accession

0001652410-26-000014

Alert Tier

5